Clinical Trial CTSUGIC80802-M
Title
Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
Principal Investigator(s)
John Murray
Details
- Protocol No. CTSUGIC80802-M
- Open Date: 12/07/2010
- Staging: Phase III
- Age Group: Adults
- Scope: National
- Objective:
- Disease Sites:
- Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
- Drugs: BAY 43-9006 (Sorafenib); Sorafenib (Nexavar)
- Participating Institutions: Baptist Hospital; Meharry Medical College
- Secondary Protocol No: Not Specified
Description
None Provided.
Eligibility
Not provided. Please call for more information.
Learn More
- Call toll-free number: 1-800-811-8480
- Use our Online self–referral form
- Print this page for your doctor
You do not have JavaScript enabled. This site works better with JavaScript turned on.
